Lista de obras - Razelle Kurzrock - Dominio Público Uruguay

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors ⬇️

artículo científico publicado el 14 de octubre de 2010

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors ⬇️

artículo científico publicado el 12 de junio de 2012

A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers

artículo científico publicado en 2019

A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease ⬇️

artículo científico publicado el 9 de mayo de 2013

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

scientific article published on 22 January 2020

A Tale of Two Histiocytic Disorders ⬇️

artículo científico publicado el 8 de enero de 2013

A cancer trial scandal and its regulatory backlash

artículo científico publicado en 2014

A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors

artículo científico publicado en 2010

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors

artículo científico publicado en 2015

A framework for genomic biomarker actionability and its use in clinical decision making

artículo científico publicado en 2014

A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal

scientific article published on March 2013

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome

artículo científico publicado en 2007

A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer

artículo científico publicado en 2011

A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.

artículo científico publicado en 2012

A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver

artículo científico publicado en 2010

A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours

artículo científico publicado en 2014

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma

artículo científico publicado en 2017

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

artículo científico publicado en 2015

A phase I clinical trial of darinaparsin in patients with refractory solid tumors.

artículo científico publicado en 2009

A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies ⬇️

artículo científico publicado el 21 de febrero de 2013

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas

artículo científico publicado en 2012

A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies

scientific article published on 09 February 2010

A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors

artículo científico publicado en 2010

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies

artículo científico publicado en 2013

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer

artículo científico publicado en 2014

A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.

artículo científico publicado en 2009

A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies

artículo científico publicado en 2011

A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma

artículo científico publicado en 2014

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors

artículo científico publicado en 2014

A pilot study of temsirolimus and body composition

artículo científico publicado en 2013

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer

artículo científico publicado en 2015

APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy

artículo científico publicado en 2018

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

artículo científico publicado en 2020

ASO Author Reflections: Circulating Tumor DNA in Peritoneal Carcinomatosis

scientific article published on 12 November 2018

ASO Author Reflections: Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases

artículo científico publicado en 2020

ATM Mutations in Cancer: Therapeutic Implications

artículo científico publicado en 2016

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

artículo científico publicado en 2015

Actionability and precision oncology

artículo científico publicado en 2015

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

artículo científico publicado en 2015

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer ⬇️

artículo científico publicado el 23 de mayo de 2011

Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies

artículo científico publicado en 2004

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial ⬇️

artículo científico publicado el 16 de julio de 2012

Adjuvant interferon in high-risk melanoma: end of the era?

artículo científico publicado en 2009

Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience

artículo científico publicado en 2012

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus

artículo científico publicado en 2014

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

artículo científico publicado en 2016

Advancing the Scope of Nursing Practice: Hepatic Arterial Catheter Removal ⬇️

artículo científico publicado el 1 de octubre de 2011

Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy

artículo científico publicado en 2020

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial

artículo científico publicado en 2019

An 84-Year-Old Woman With an Indolent B-Cell Lymphoma

artículo científico publicado en 2016

An appraisal of drug development timelines in the Era of precision oncology

artículo científico publicado en 2016

An avatar for precision cancer therapy

artículo científico publicado en 2018

Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma

artículo científico publicado en 2014

Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities

artículo científico publicado en 2017

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic

artículo científico publicado en 2014

Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction and Gastric Adenocarcinoma

artículo científico publicado en 2018

Analysis of Drug Development Paradigms for Immune Checkpoint inhibitors

artículo científico publicado en 2017

Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies

scientific article published on 13 July 2018

Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics

scientific article published on 15 November 2018

Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics

artículo científico publicado en 2018

Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma

artículo científico publicado en 2003

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

artículo científico publicado en 2014

Androgen receptors beyond prostate cancer: an old marker as a new target

artículo científico publicado en 2015

Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing

scientific article published on 09 July 2020

Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?

artículo científico publicado en 2010

Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy ⬇️

artículo científico publicado el 15 de diciembre de 2011

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease

artículo científico publicado en 2017

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors

artículo científico publicado en 2014

Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis

artículo científico publicado en 2016

Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib

artículo científico publicado en 2016

Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience

scientific article published on 19 September 2020

Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress

artículo científico publicado en 2015

Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53

artículo científico publicado en 2002

Autophagy as a target for anticancer therapy

artículo científico publicado en 2011

BAP1: Not just a BRCA1-associated protein

artículo científico publicado en 2020

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

artículo científico

BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease

artículo científico publicado en 2014

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

artículo científico publicado en 2015

BRAF mutation as a novel driver of eosinophilic cystitis

artículo científico publicado en 2017

BRAF mutation testing with a rapid, fully integrated molecular diagnostics system

artículo científico publicado en 2015

BRAF mutations in advanced cancers: clinical characteristics and outcomes

artículo científico publicado en 2011

BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency ⬇️

artículo científico publicado el 21 de febrero de 2012

Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit

artículo científico publicado en 2013

Basal Cell Carcinoma: Management of Advanced or Metastatic Cancer with Checkpoint Inhibitors and Concurrent Paradoxical Development of New Superficial Tumors

scientific article published on 25 February 2020

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation ⬇️

artículo científico publicado el 12 de febrero de 2013

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma

artículo científico

Binding partners for curcumin in human schwannoma cells: biologic implications

artículo científico publicado en 2012

Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway

artículo científico publicado en 2013

Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service

artículo científico publicado en 2012

Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center

artículo científico publicado en 2015

Bringing Blood-Based Molecular Testing to the Clinic

artículo científico publicado en 2016

CASE 1. Langerhans cell histiocytosis of the thyroid

artículo científico publicado en 2006

CAT scan reveals BAT sign

artículo científico publicado en 2007

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.

artículo científico publicado en 2016

Cancer research in the United States: A critical review of current status and proposal for alternative models

scientific article published on 14 May 2018

Cancer: the road to Amiens

scientific article published on 08 December 2008

Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome

artículo científico publicado en 2004

Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics ⬇️

artículo científico publicado el 25 de marzo de 2011

Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report

artículo científico publicado en 2015

Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics

artículo científico publicado en 2016

Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology

artículo científico publicado en 2017

Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors

artículo científico publicado en 2011

Challenges and perspective of drug repurposing strategies in early phase clinical trials

artículo científico publicado en 2015

Challenging Standard-of-Care Paradigms in the Precision Oncology Era.

artículo científico publicado en 2018

Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies

artículo científico publicado en 2012

Characteristics and survival of patients with advanced cancer and p53 mutations

artículo científico publicado en 2014

Chemotherapy resistance and retreatment: a dogma revisited

artículo científico publicado en 2010

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic

artículo científico publicado en 2020

Click chemistry, 3D-printing, and omics: the future of drug development

artículo científico publicado en 2015

Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience

artículo científico publicado en 2014

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer

scientific article published on 04 December 2019

Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome

artículo científico publicado en 2002

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients

artículo científico publicado en 2020

Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience

artículo científico publicado en 2009

Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience

artículo científico publicado en 2010

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial

artículo científico publicado en 2018

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

artículo científico publicado en 2015

Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways

artículo científico publicado en 2011

Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations

artículo científico publicado en 2013

Combining targeted therapies: practical issues to consider at the bench and bedside

artículo científico publicado en 2010

Community-acquired methicillin-resistant Staphylococcus aureus skin infection: an emerging clinical problem

artículo científico publicado en 2004

Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer

scientific article published on 23 August 2018

Compliance in Early-Phase Cancer Clinical Trials Research ⬇️

artículo científico publicado el 1 de enero de 2013

Comprehensive Genomic Landscape and Precision Therapeutic Approach in Biliary Tract Cancers

scientific article published on 23 July 2020

Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials

scientific article published on 21 December 2018

Computed axial tomography scanning (CT scan).

artículo científico publicado en 2006

Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden

artículo científico publicado en 2020

Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.

artículo científico publicado en 2009

Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus

artículo científico publicado en 2017

Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit

artículo científico publicado en 2017

Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells

artículo científico publicado en 2008

Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated prot

artículo científico publicado en 2005

Cutaneous Castleman disease ⬇️

artículo científico publicado el 26 de abril de 2012

Cutaneous castleman's disease responds to anti interleukin-6 treatment

artículo científico publicado en 2007

Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions

scientific article published on 04 September 2020

Cyclin alterations in diverse cancers: Outcome and co-amplification network

artículo científico publicado en 2015

Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics

artículo científico publicado en 2015

Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-alpha-308 G/A IL6-174G/C and IL8-251T/A.

artículo científico publicado en 2007

Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis

scientific article published on 01 December 2004

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

artículo científico publicado en 2012

Debunking the Delusion That Precision Oncology Is an Illusion

artículo científico publicado en 2017

Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.

artículo científico publicado en 2009

Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors

artículo científico publicado en 2014

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay

artículo científico publicado en 2016

Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.

artículo científico publicado en 2009

Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies

scientific article published on 16 September 2019

Development of curcumin as an epigenetic agent

artículo científico publicado en 2010

Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance

artículo científico publicado en 2006

Dodging a dogma: is treating beyond progression beneficial? ⬇️

artículo científico publicado el 27 de febrero de 2013

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

artículo científico publicado en 2014

Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver

artículo científico publicado en 2015

Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver

artículo científico publicado en 2012

Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience

artículo científico publicado en 2018

Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients.

artículo científico publicado en 2017

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers

artículo científico publicado en 2016

Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns

artículo científico publicado en 2017

Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013.

artículo científico publicado en 2016

Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden

scientific article published on 15 May 2020

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

scientific article published on 20 April 2020

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer

artículo científico publicado en 2014

Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer

artículo científico publicado en 2013

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors

artículo científico publicado en 2014

Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

artículo científico publicado en 2014

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials

artículo científico publicado en 2008

Effect of Dual Vascular Input Functions on CT Perfusion Parameter Values and Reproducibility in Liver Tumors and Normal Liver ⬇️

artículo científico publicado el 1 de julio de 2012

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors

artículo científico publicado en 2015

Effect of Sampling Frequency on Perfusion Values in Perfusion CT of Lung Tumors ⬇️

artículo científico publicado el 1 de febrero de 2013

Effect of duration of scan acquisition on CT perfusion parameter values in primary and metastatic tumors in the lung ⬇️

artículo científico publicado el 13 de junio de 2013

Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial

artículo científico publicado en 2011

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds

artículo científico publicado en 2020

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

artículo científico publicado en 2002

Electronic clinical challenges and images in GI. Image 2. Extensive bilateral extracranial subcutaneous fluid collection

artículo científico publicado en 2009

Epidermal growth factor receptor mutation and diverse tumors: case report and concise literature review

scientific article published on 07 March 2010

Epstein-Barr virus and cancer

artículo científico publicado en 2004

Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study

artículo científico publicado en 2006

Equipoise lost: ethics, costs, and the regulation of cancer clinical research

artículo científico publicado en 2010

Erdheim-Chester disease: characteristics and management

artículo científico

Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases

scientific article published on 01 April 2016

Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

artículo científico publicado en 2015

Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy

artículo científico publicado en 2014

Evaluation of liposomal curcumin cytochrome p450 metabolism

artículo científico publicado en 2010

Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy

artículo científico publicado en 2012

Ewing's sarcoma: overcoming the therapeutic plateau

artículo científico publicado en 2012

Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores

artículo científico publicado en 2017

Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies

artículo científico publicado en 2013

Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases

artículo científico publicado en 2010

Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials

artículo científico publicado en 2015

Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients

artículo científico publicado en 2016

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity

artículo científico publicado en 2020

Eyelash trichomegaly: review of congenital, acquired, and drug‐associated etiologies for elongation of the eyelashes ⬇️

artículo científico publicado el 1 de junio de 2012

FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors

artículo científico publicado en 2016

Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review

artículo científico publicado en 2016

Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy ⬇️

artículo científico publicado el 2 de marzo de 2013

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

artículo científico publicado en 2003

Farnesyltransferase inhibitors

scientific article published on 01 March 2005

Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies

artículo científico publicado en 2002

Farnesyltransferase inhibitors: where are we now?

artículo científico publicado en 2010

Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications

artículo científico publicado en 2015

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

artículo científico publicado en 2015

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

scientific article published on 10 December 2019

Fool’s gold, lost treasures, and the randomized clinical trial ⬇️

artículo científico publicado el 16 de abril de 2013

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm

scientific article published on 29 September 2020

Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies

artículo científico publicado en 2002

GNAS, GNAQ, and GNA11 Alterations in Patients With Diverse Cancers

artículo científico publicado en 2018

Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes

artículo científico publicado en 2009

Genetics on a WHIM ⬇️

artículo científico publicado el 20 de septiembre de 2013

Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients

artículo científico publicado en 2018

Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing

artículo científico publicado en 2017

Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival

Genomic Landscape of Malignant Mesotheliomas

artículo científico publicado en 2016

Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics

scientific article published on 18 July 2019

Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps

artículo científico publicado en 2015

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

artículo científico publicado en 2019

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies

artículo científico publicado en 2017

Genomic landscape of salivary gland tumors

artículo científico publicado en 2015

Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics

artículo científico publicado en 2016

Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm

artículo científico publicado en 2016

Genomics of Immunotherapy-Associated Hyperprogressors-Response

artículo científico publicado en 2017

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design

scientific article published on 09 February 2016

Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications

artículo científico publicado en 2013

HER2 aberrations in cancer: implications for therapy

artículo científico publicado en 2014

HER2 expression status in diverse cancers: review of results from 37,992 patients

artículo científico publicado en 2015

Health policy: The right to try is embodied in the right to die.

artículo científico publicado en 2016

Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview

artículo científico publicado en 2004

Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience

artículo científico publicado en 2013

High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers

artículo científico publicado en 2020

High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations

artículo científico publicado en 2017

Human epidermal receptor 2–amplified salivary duct carcinoma: Regression with dual human epidermal receptor 2 inhibition and anti–vascular endothelial growth factor combination treatment ⬇️

artículo científico publicado el 19 de octubre de 2013

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced cancers of the gastrointestinal tract or anus.

artículo científico publicado en 2018

Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy

artículo científico publicado en 2017

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?

scientific article published on 20 November 2019

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate

artículo científico publicado en 2017

I have good news! You have leukemia

artículo científico publicado en 2007

IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers

artículo científico publicado en 2020

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing

artículo científico publicado en 2018

Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing

artículo científico publicado en 2014

Identification of targets for prostate cancer immunotherapy

scientific article published on 06 January 2019

Idiopathic multicentric Castleman's disease: a systematic literature review

artículo científico publicado en 2016

Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia

Immune Escape of AML Cells after Transplantation

artículo científico publicado en 2019

Immune profiling and immunotherapeutic targets in pancreatic cancer

artículo científico publicado en 2021

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials

artículo científico publicado en 2015

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval

artículo científico publicado en 2015

Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples

artículo científico publicado en 2014

Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair ⬇️

artículo científico publicado el 1 de septiembre de 2003

Improving the Institutional Submission and Approval Process for Clinical Research Protocols in Oncology

artículo científico publicado en 2007

In Reply

Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response

scientific article published on 25 March 2014

Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides

artículo científico publicado en 2008

Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies

artículo científico publicado en 2011

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study

artículo científico publicado en 2017

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors

artículo científico publicado en 2012

Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver – Will it hit the moving target? ⬇️

artículo científico publicado el 21 de septiembre de 2011

Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act.

artículo científico publicado en 2017

Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer

scientific article published on 12 December 2018

Interleukin-6 and its receptor in cancer: implications for translational therapeutics

artículo científico publicado en 2007

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease

artículo científico publicado en 2020

International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease

artículo científico publicado en 2017

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

artículo científico publicado en 2018

Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis

artículo científico publicado en 2012

Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study

artículo científico publicado en 2014

Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response

artículo científico publicado en 2020

It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy

artículo científico publicado en 2012

JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease

artículo científico publicado en 2017

JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis

artículo científico publicado en 2018

Juice plus or toxicity plus

artículo científico publicado en 2010

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors

artículo científico publicado en 2012

Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors

artículo científico publicado en 2016

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology

scientific article published on 19 September 2018

Letter responds to comment on "intention-to-treat analysis in precision oncology: A cautious interpretation"

scientific article published on 21 August 2020

Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer

artículo científico publicado en 2007

Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis

artículo científico publicado en 2005

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine

artículo científico publicado en 2019

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials

artículo científico publicado en 2020

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

artículo científico publicado en 2014

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit

artículo científico publicado en 2014

MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors

artículo científico publicado en 2014

MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis

artículo científico publicado en 2018

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors

artículo científico publicado en 2013

MHC-I genotype and tumor mutational burden predict response to immunotherapy

scientific article published on 19 May 2020

MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo

artículo científico publicado en 2010

Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials

artículo científico publicado en 2020

Mechanistic basis for overcoming platinum resistance using copper chelating agents

artículo científico publicado en 2012

Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib

artículo científico publicado en 2008

Meir Wetzler, MD.

artículo científico publicado en 2015

Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications

artículo científico publicado en 2015

Merkel Cell Polyomavirus and HPV-17 Associated With Cutaneous Squamous Cell Carcinoma Arising in a Patient With Melanoma Treated With the BRAF Inhibitor Dabrafenib ⬇️

artículo científico publicado el 1 de marzo de 2013

Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes

artículo científico publicado en 2018

Metastasis--an alternative hypothesis

artículo científico publicado en 2005

Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy

artículo científico publicado en 2016

Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies

artículo científico publicado en 2013

Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy

artículo científico publicado en 2019

Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual

artículo científico publicado en 2016

Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

artículo científico publicado en 2019

Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis

scientific article published on 23 April 2019

Molecular Tumor Boards: Realizing Precision Oncology Therapy

artículo científico publicado en 2017

Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art

artículo científico publicado en 2014

Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer

artículo científico publicado en 2015

Molecular epidemiology, cancer-related symptoms, and cytokines pathway

artículo científico publicado en 2008

Molecular imaging of Bcr-Abl phosphokinase in a xenograft model

artículo científico publicado en 2009

Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model

artículo científico publicado en 2009

Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology

artículo científico publicado en 2015

Molecular landscape of pancreatic cancer: implications for current clinical trials

artículo científico publicado en 2015

Molecular landscape of prostate cancer: implications for current clinical trials

artículo científico publicado en 2015

Molecular profiling and the reclassification of cancer: divide and conquer

artículo científico publicado en 2013

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

artículo científico publicado en 2019

Molecular tumor board: the University of California-San Diego Moores Cancer Center experience

artículo científico publicado en 2014

Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine

artículo científico publicado en 2017

Morphoproteomic Profiling of the Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Desmoplastic Small Round Cell Tumor (EWS/WT1), Ewing’s Sarcoma (EWS/FLI1) and Wilms’ Tumor(WT1) ⬇️

artículo científico publicado el 29 de julio de 2013

Multiple gene aberrations and breast cancer: lessons from super-responders

artículo científico publicado en 2015

Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib

artículo científico publicado en 2008

Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues

scientific article published on 29 September 2019

My personal experiences at the BEST Medical Center: A day in the clinic-the afternoon

artículo científico publicado en 2016

My personal experiences at the BEST Medical Center: A day in the clinic-the morning

artículo científico publicado en 2016

Myelodysplastic syndrome overview

artículo científico publicado en 2002

NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys

artículo científico publicado en 2015

NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies

artículo científico publicado en 2014

NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations

artículo científico publicado en 2014

New drug approvals in oncology

scientific article published on 04 February 2020

New therapeutic approaches to overcoming resistant EGFR exon 20 alterations

artículo científico publicado en 2020

Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies

artículo científico publicado en 2017

Next generation predictive biomarkers for immune checkpoint inhibition

artículo científico publicado en 2016

Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer

artículo científico publicado en 2015

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

artículo científico publicado en 2015

Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability

artículo científico publicado en 2017

Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma

artículo científico publicado en 2018

Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies

scientific article published on 29 March 2019

Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing

artículo científico publicado en 2018

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment ⬇️

artículo científico publicado el 1 de febrero de 2013

Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies

scientific article published on 05 December 2006

Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies

artículo científico publicado en 2015

Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors

artículo científico publicado en 2014

Novel therapeutic targets in non-small cell lung cancer

artículo científico publicado en 2011

Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis

artículo científico publicado en 2004

Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells

scientific article published on 01 September 2006

Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines

artículo científico publicado en 2015

Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors.

artículo científico publicado en 2018

On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients

artículo científico publicado en 2015

Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program

artículo científico publicado en 2011

Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience

artículo científico publicado en 2012

Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009 ⬇️

artículo científico publicado el 26 de septiembre de 2012

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials

artículo científico publicado en 2014

Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic

artículo científico publicado en 2011

Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program

artículo científico publicado en 2014

Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.

artículo científico publicado en 2016

Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience

artículo científico publicado en 2011

Overcoming platinum resistance through the use of a copper-lowering agent

artículo científico publicado en 2012

P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy

scientific article published on May 2013

PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas

artículo científico publicado en 2016

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

artículo científico publicado en 2015

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

artículo científico publicado en 2012

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials

artículo científico publicado en 2012

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers

artículo científico publicado en 2011

PIK3CA mutations in advanced cancers: characteristics and outcomes

artículo científico publicado en 2012

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

artículo científico publicado en 2011

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.

artículo científico publicado en 2017

Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment

artículo científico publicado en 2010

Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus

artículo científico publicado en 2014

Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer

artículo científico publicado en 2012

Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses

artículo científico publicado en 2014

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative

artículo científico publicado en 2012

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

scientific article published on 08 March 2019

Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases

scientific article published on 23 December 2015

Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer

artículo científico publicado en 2011

Phase 1 clinical trials for sarcomas: the cutting edge ⬇️

artículo científico publicado el 1 de julio de 2011

Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience

artículo científico publicado en 2010

Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.

artículo científico publicado en 2010

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignancies

scientific article published on 01 November 2018

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors

artículo científico publicado en 2014

Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma

artículo científico publicado en 2015

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies

artículo científico publicado en 2014

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer

artículo científico publicado en 2010

Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors

artículo científico publicado en 2011

Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma ⬇️

artículo científico publicado en 2015

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer

artículo científico publicado en 2016

Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors ⬇️

artículo científico publicado el 23 de abril de 2012

Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer

scientific article published on 01 December 2010

Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer

artículo científico publicado en 2014

Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement

artículo científico publicado en 2010

Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement

artículo científico publicado en 2010

Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer

artículo científico publicado en 2016

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer

artículo científico publicado en 2013

Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience

artículo científico publicado en 2011

Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience

artículo científico publicado en 2009

Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience

artículo científico publicado en 2010

Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy

artículo científico publicado en 2015

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors

artículo científico publicado en 2013

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer

artículo científico publicado en 2010

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

artículo científico publicado en 2016

Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors

scientific article published on 15 February 2020

Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse

artículo científico publicado en 2010

Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.

artículo científico publicado en 2013

Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors

artículo científico publicado en 2013

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes

artículo científico publicado en 2005

Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome

artículo científico publicado en 2008

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

artículo científico publicado en 2014

Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy

artículo científico publicado en 2015

Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers

artículo científico publicado en 2008

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers

scientific article published on 26 April 2018

Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity

artículo científico publicado en 2012

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors

artículo científico publicado en 2017

Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies

artículo científico publicado en 2009

Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer

artículo científico publicado en 2011

Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity

artículo científico publicado en 2011

Phase I trial of valproic acid and lenalidomide in patients with advanced cancer

artículo científico publicado en 2015

Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia

artículo científico publicado en 2008

Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.

artículo científico publicado en 2006

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

artículo científico publicado en 2017

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma

artículo científico publicado en 2017

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

artículo científico publicado en 2004

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

artículo científico publicado en 2003

Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome

artículo científico publicado en 2006

Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series

artículo científico publicado en 2004

Phase II trial of curcumin in patients with advanced pancreatic cancer

artículo científico publicado en 2008

Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma

artículo científico publicado en 2017

Phase I trials as valid therapeutic options for patients with cancer

artículo científico publicado en 2019

Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness

artículo científico publicado en 2019

Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics

artículo científico publicado en 2003

Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities

Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas

scientific article published on 01 August 2004

Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer

artículo científico publicado en 2009

Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver

scientific article published on 01 June 2007

Polycystic ovary syndrome in men.

artículo científico publicado en 2017

Polycystic ovary syndrome in men: Stein-Leventhal syndrome revisited

artículo científico publicado en 2006

Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides

artículo científico publicado en 2008

Posterior Reversible Encephalopathy Syndrome: More Than Meets the Eye ⬇️

artículo científico publicado el 3 de junio de 2013

Pre-treatment endogenous interleukin-1 receptor antagonist (IL-1Ra) levels in metastatic colorectal cancer (mCRC) patients are associated with clinical outcomes after anti-interleukin-1a therapy (MABp1)

artículo científico publicado en 2017

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience

artículo científico publicado en 2016

Precision medicine: lessons learned from the SHIVA trial

artículo científico publicado en 2015

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes

artículo científico publicado en 2015

Precision oncology: the intention-to-treat analysis fallacy

scientific article published on 15 May 2020

Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs ⬇️

artículo científico publicado el 4 de noviembre de 2013

Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival

artículo científico publicado en 2018

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

artículo científico publicado en 2016

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors

artículo científico publicado en 2018

Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience

artículo científico publicado en 2011

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma.

artículo científico publicado en 2019

Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases

artículo científico publicado en 2020

Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies

artículo científico publicado en 2019

Progression‐free survival 2: Is it ready for prime time?

artículo científico publicado en 2022

Project Zero Delay: a process for accelerating the activation of cancer clinical trials

artículo científico publicado en 2009

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients

scholarly article by Sarabjot Pabla et al published 1 February 2019 in Journal for Immunotherapy of Cancer

Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients

scientific article published on 10 June 2020

Promoting Precision Cancer Medicine through a Community-Driven Knowledgebase

artículo científico publicado en 2014

Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders

artículo científico publicado en 2014

Purine analogues in advanced T-cell lymphoid malignancies

artículo científico publicado en 2006

R1507, an Anti-Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antibody, and EWS/FLI-1 siRNA in Ewing's Sarcoma: Convergence at the IGF/IGFR/Akt Axis ⬇️

artículo científico publicado el 11 de octubre de 2011

RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials

artículo científico publicado en 2013

REPLY to MS#JAAD-D-20-02240: Effective Therapy for Advanced Basal Cell Carcinoma

artículo científico publicado en 2020

RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients

artículo científico publicado en 2016

Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response

Rapid Response to Vemurafenib in a Heavily Pretreated Patient With Hairy Cell Leukemia and a BRAF Mutation ⬇️

artículo científico publicado el 3 de junio de 2013

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach

artículo científico publicado en 2017

Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of Disease

Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease

artículo científico publicado en 2019

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

artículo científico publicado en 2020

Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies

artículo científico publicado en 2002

Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells

artículo científico publicado en 2002

Refractory Hodgkin lymphoma responds to pentostatin (2'-deoxycoformycin).

artículo científico publicado en 2006

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients

scientific article published on 01 October 2019

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[<sup>18</sup>F]FDG PET (positron emission tomography) scan in cancer patients

scientific article published on 09 December 2020

Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors

artículo científico publicado en 2015

Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer

scholarly article by Jacob J Adashek et al published 22 May 2019 in Journal for Immunotherapy of Cancer

Reply to A. Levy et al.

artículo científico publicado en 2013

Reply to J.J. Tao et al

scientific article published on 01 June 2018

Reproducibility of CT Perfusion Parameters in Liver Tumors and Normal Liver ⬇️

artículo científico publicado el 25 de julio de 2011

Reproducibility of Perfusion Parameters Obtained From Perfusion CT in Lung Tumors ⬇️

artículo científico publicado el 1 de julio de 2011

Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses

artículo científico publicado en 2010

Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors

artículo científico publicado en 2010

Response

artículo científico publicado en 2016

Response of Lymphangioleiomyomatosis to a Mammalian Target of Rapamycin Inhibitor (Temsirolimus) –Based Treatment ⬇️

artículo científico publicado el 24 de enero de 2011

Response of histiocytoses to imatinib mesylate: fire to ashes

artículo científico publicado en 2010

Responses to Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Metaplastic Carcinoma of the Breast: Biologic Rationale and Implications for Stem-Cell Research in Breast Cancer ⬇️

artículo científico publicado el 11 de abril de 2011

Retreatment after secondary resistance or mixed response: a pilot study

artículo científico publicado en 2013

Review of precision cancer medicine: Evolution of the treatment paradigm

scientific article published on 31 March 2020

Revisiting Epidermal Growth Factor Receptor () Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies

Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population

artículo científico publicado en 2013

Risks and benefits of phase 1 oncology trials, revisited

artículo científico publicado en 2005

Role of ultra-violet mutational signature versus tumor mutation burden in predicting response to immunotherapy

artículo científico publicado en 2020

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

scholarly article by Matthew J Reilley et al published 16 November 2018 in Journal for Immunotherapy of Cancer

STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications

artículo científico publicado en 2021

SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer

artículo científico publicado en 2015

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

artículo científico publicado en 2020

Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors ⬇️

artículo científico publicado el 27 de diciembre de 2011

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial ⬇️

artículo científico publicado el 16 de julio de 2012

Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies

artículo científico publicado en 2012

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

artículo científico publicado en 2009

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2007

Salirasib in the treatment of pancreatic cancer

artículo científico publicado en 2010

Salivary Duct Carcinoma: Targeting the Phosphatidylinositol 3-Kinase Pathway by Blocking Mammalian Target of Rapamycin With Temsirolimus ⬇️

artículo científico publicado el 15 de agosto de 2011

Sarcoidosis and malignancy

artículo científico publicado en 2007

Schnitzler syndrome associated with L265P mutation

Selpercatinib Aimed at RET-Altered Cancers

artículo científico publicado en 2020

Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses

artículo científico publicado en 2003

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease

artículo científico publicado en 2010

Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease

artículo científico publicado en 2015

Snapshot: Trial Types in Precision Medicine

scientific article published on 01 April 2020

Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types

artículo científico publicado en 2015

Standardized uptake value (SUVmax) in 18F-FDG PET/CT is correlated with the total number of main oncogenic anomalies in cancer patients

artículo científico publicado en 2020

Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer

artículo científico publicado en 2017

Studies in target-based treatment

artículo científico publicado en 2007

Studies in target-based treatment

artículo científico publicado en 2007

Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.

artículo científico publicado en 2009

Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade

article

Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL)

artículo científico publicado en 2018

Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).

artículo científico publicado en 2010

Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha

artículo científico publicado en 2005

Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors.

artículo científico publicado en 2009

Survival implications of the relationship between tissue versus circulating tumor DNA TP53 mutations - a perspective from a real-world precision medicine cohort

artículo científico publicado en 2020

Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience

artículo científico publicado en 2012

Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience

artículo científico publicado en 2009

Sweet's syndrome revisited: a review of disease concepts

artículo científico publicado en 2003

Sweet's syndrome: a review of current treatment options

artículo científico publicado en 2002

Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic

artículo científico publicado en 2014

TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics

artículo científico publicado en 2016

TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET).

artículo científico publicado en 2018

Target validation using Phase 0 clinical trials: Promises and pitfalls

artículo científico publicado en 2009

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations

artículo científico publicado en 2013

Targeted Inhibitors: Novel Strategies for Response Optimization

artículo científico publicado en 2015

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience

artículo científico publicado en 2014

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

artículo científico publicado en 2018

Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures

artículo científico publicado en 2011

Targeted therapies: What have we learned from SHIVA?

artículo científico publicado en 2016

Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome

artículo científico

Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome

artículo científico

Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome.

artículo científico publicado en 2014

Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

scientific article published on 15 June 2010

Targeted therapy in rare cancers—adopting the orphans ⬇️

artículo científico publicado el 11 de septiembre de 2012

Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials

artículo científico publicado en 2013

Targeting fusions for improved outcomes in oncology treatment

scientific article published on 03 December 2019

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab

artículo científico publicado en 2014

Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist ⬇️

artículo científico publicado el 20 de agosto de 2012

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab

artículo científico publicado en 2016

Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors.

artículo científico publicado en 2017

Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions ⬇️

artículo científico publicado el 28 de noviembre de 2012

Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients

artículo científico publicado en 2017

Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting

artículo científico publicado en 2019

The "shield sign" in two men with metastatic salivary duct carcinoma to the skin: cutaneous metastases presenting as carcinoma hemorrhagiectoides ⬇️

artículo científico publicado el 1 de septiembre de 2012

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

scientific article published on 14 October 2020

The Conundrum of Genetic "Drivers" in Benign Conditions

artículo científico publicado en 2016

The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

scientific article published on 09 January 2020

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

artículo científico publicado en 2015

The Karabus Affair Speaks to Larger Issues for American Academic and Medical Centers ⬇️

artículo científico publicado el 1 de mayo de 2013

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match

artículo científico publicado en 2018

The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine

scientific article published on 01 January 2020

The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA.

artículo científico publicado en 2017

The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers

artículo científico publicado en 2015

The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab

artículo científico publicado en 2015

The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases.

artículo científico publicado en 2015

The biology of Hepatocellular carcinoma: implications for genomic and immune therapies

artículo científico

The changing face of phase 1 cancer clinical trials: new challenges in study requirements

scientific article published on April 2009

The checklist: BEST medical center employment requirements 2015.

artículo científico publicado en 2015

The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia

scientific article published on 01 August 2002

The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer

artículo científico publicado en 2016

The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines

artículo científico publicado en 2007

The importance of greater speed in drug development for advanced malignancies.

artículo científico publicado en 2018

The influence of tumor necrosis factor-alpha -308 G/A and IL-6 -174 G/C on pain and analgesia response in lung cancer patients receiving supportive care

artículo científico publicado en 2008

The inverted pyramid of biomarker-driven trials

artículo científico publicado en 2011

The paradox of cancer genes in non-malignant conditions: implications for precision medicine

artículo científico publicado en 2020

The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes

artículo científico publicado en 2008

The role of investigational therapy in management of patients with advanced metastatic malignancy

scientific article published on 08 December 2008

Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer

scientific article published on 04 August 2020

Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited

artículo científico publicado en 2005

Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses

artículo científico publicado en 2013

Timing of palliative care referral and symptom burden in phase 1 cancer patients: a retrospective cohort study

artículo científico publicado en 2010

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients

artículo científico

Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers

scientific article published on 24 March 2020

Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms

artículo científico

Transcriptomic silencing as a potential mechanism of treatment resistance

scientific article published on 04 June 2020

Transcriptomics and Solid Tumors: The Next Frontier in Precision Cancer Medicine

scientific article published on 17 September 2020

Transformation of human mesenchymal cells and skin fibroblasts into hematopoietic cells

artículo científico publicado en 2011

Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases

artículo científico publicado en 2013

Treatment of Patients With Advanced Neurofibromatosis Type 2 With Novel Molecularly Targeted Therapies: From Bench to Bedside ⬇️

artículo científico publicado el 27 de diciembre de 2011

Treatment of chronic myelogenous leukemia as a paradigm for solid tumors: how targeted agents in newly diagnosed disease transformed outcomes

artículo científico publicado en 2012

Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib

artículo científico publicado en 2008

Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents

artículo científico publicado en 2014

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

artículo científico publicado en 2017

Tumor mutational burden is not predictive of cytotoxic chemotherapy response

artículo científico publicado en 2020

Turmeric and green tea: a recipe for the treatment of B-chronic lymphocytic leukemia

scientific article published on February 2009

Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics

artículo científico publicado en 2005

Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial

artículo científico publicado en 2009

Uncommon tumors and exceptional therapies: paradox or paradigm?

artículo científico publicado en 2007

Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management

artículo científico publicado en 2015

Unilateral Proptosis ⬇️

artículo científico publicado el 13 de febrero de 2013

Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms

scientific article published on 03 September 2020

Unique molecular landscapes in cancer: implications for individualized, curated drug combinations

artículo científico publicado en 2014

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms

artículo científico publicado en 2014

Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis

artículo científico publicado en 2016

Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients

artículo científico publicado en 2016

Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary

artículo científico publicado en 2017

Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma

artículo científico

VEGF and dual-EGFR inhibition in colorectal cancer

artículo científico publicado en 2015

VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy

artículo científico publicado en 2015

Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials

artículo científico publicado en 2016

Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center

artículo científico publicado en 2011

Vascular endothelial growth factor and its relationship to inflammatory mediators

artículo científico publicado en 2007

Warning signal: Unaware of an in absentia conviction, South African cancer specialist jailed on return to the United Arab Emirates ⬇️

artículo científico publicado el 1 de enero de 2013

Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial

artículo científico publicado en 2013

Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer

artículo científico publicado en 2015

Lista de obras de Razelle Kurzrock

A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors ⬇️

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors ⬇️

A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers

A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease ⬇️

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

A Tale of Two Histiocytic Disorders ⬇️

A cancer trial scandal and its regulatory backlash

A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors

A framework for genomic biomarker actionability and its use in clinical decision making

A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome

A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer

A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.

A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver

A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

A phase I clinical trial of darinaparsin in patients with refractory solid tumors.

A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies ⬇️

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas

A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies

A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer

A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.

A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies

A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors

A pilot study of temsirolimus and body composition

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer

APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

ASO Author Reflections: Circulating Tumor DNA in Peritoneal Carcinomatosis

ASO Author Reflections: Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases

ATM Mutations in Cancer: Therapeutic Implications

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

Actionability and precision oncology

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer ⬇️

Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial ⬇️

Adjuvant interferon in high-risk melanoma: end of the era?

Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

Advancing the Scope of Nursing Practice: Hepatic Arterial Catheter Removal ⬇️

Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial

An 84-Year-Old Woman With an Indolent B-Cell Lymphoma

An appraisal of drug development timelines in the Era of precision oncology

An avatar for precision cancer therapy

Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma

Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic

Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction and Gastric Adenocarcinoma

Analysis of Drug Development Paradigms for Immune Checkpoint inhibitors

Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies

Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics

Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics

Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

Androgen receptors beyond prostate cancer: an old marker as a new target

Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing

Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?

Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy ⬇️

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors

Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis

Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib

Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience

Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress

Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53

Autophagy as a target for anticancer therapy

BAP1: Not just a BRCA1-associated protein

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease

BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

BRAF mutation as a novel driver of eosinophilic cystitis